Click here to read the previous Australian cannabis outlook.

The Australian cannabis market is moving along as regulations fall into place for the sector to keep expanding.

While the current rules may make the market appear at a standstill, recent approvals show the momentum for a vibrant medical cannabis industry will carry on in 2021.

Even though companies on the ground don’t expect to see recreational use become legal throughout 2021, the medical cannabis market is still expected to continue ahead with stronger numbers.

Here the Investing News Network (INN) offers some key points on what may be ahead for the Australian cannabis market in 2021.

Australian cannabis outlook 2021: Medical still accounts for growth in the space

As part of its Oceania Cannabis Report: Second Edition business report, international drug research firm Prohibition Partners indicated medical cannabis will account for approximately 40 percent of the US$1.55 billion total the entire industry in Oceania is expected to be worth by 2024.

“Let’s build a very successful business based on medicinal cannabis… we’ve got to ride the global wave of global acceptance,” Brett Schwarz, CFO and corporate advisor with privately held firm Cannatrek told INN.

Schwarz explained it’s hard to project when exactly Australia may legalize recreational use, a key catalyst for the development of a cannabis market.

“We will one day, but we can’t say whether it’s in one year or five years,” said Schwarz. “There are more politicians talking about it, there are more doctors talking about it. that I think that it will come in time.”

The Cannatrek executive was cautious of expecting recreational cannabis to open anytime soon, instead opting to place his emphasis on what’s ahead for the medical market.

A study from FreshLeaf Analytics pegged the value of the medical market in Australia for 2020 at AU$95 million for sales in the year.

“Australia is a maturing market, not mature but maturing, and I think the patients are seeing that, so they’re feeling more comfortable,” Schwarz said.

In a portion of the study from Prohibition Partners, Roby Zomer co-founder, managing director and CEO of MGC Pharma (ASX:MXC,OTC Pink:MGCLF) said more education is driving up the number of patients realizing cannabis is the right choice for them, alongside with medical professionals becoming more comfortable prescribing it.

“This is not only driving legislation change around the world but driving demand for quality medicinal cannabis products,” the MCG Pharma executive said.

The trajectory of growth is clear to see for the medical cannabis marketplace in Australia. According to FreshLeaf Analytics, product availability has quickly risen in the latter half of 2020 to now offer patients 150 items.

The research firm also indicated at the end of 2020 there were 30,000 registered patients allowed to purchase medical cannabis in the country.

“Recent price decline has brought the illegal and legal markets to parity and has put us in line, from a pricing perspective, with more mature markets such as Canada,” the study indicated.

Australian cannabis outlook 2021: CBD set for 2021 push

In December, the Australian regulatory agency in charge of the rules of medical cannabis, the Therapeutic Goods Administration (TGA) gave the green light for low dose cannabidiol (CBD) to become available through over-the-counter methods without a prescription.

In the document, the TGA indicated this new ruling will officially come into effect starting in February.

“That’s very exciting, that’s the maturity,” Schwarz told INN about the TGA approval.

These products will need to be approved by the TGA and make it into the Australian Register of Therapeutic Goods (ARTG). According to the regulatory agency no products have yet made it.

Althea Group Holdings (ASX:AGH) CEO Josh Fegan said the company was glad to see the TGA’s decision to alongside allow these products for sale over-the-counter, to also increase the maximum recommended daily dose.

“This decision provides confirmation of that marketplace,” Fegan said as he confirmed his firm will be working to make products available through this ruling.

Australian cannabis outlook 2021: Investor Takeaway

Investors in the Australian cannabis market have watched the sector slowly develop over time to the place it is now.

Thanks to an expanding medical market the sector has much to look forward to. However, a growing potential for international export has become available for the sector as well.

Schwarz told INN cannabis companies in the country want to prove that Australia can be served by their operations at the same time that an international opportunity follows closely behind as his firm eyes exports to Europe and throughout Asia.

As companies continue to expand according to the market needs growing pains could be expected as these players set themselves up to capitalize on the patient growth in Australia.

Don’t forget to follow us @INN_Australia for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or “the Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced the hiring of CPG industry veteran Ty Gent as the Company’s new Chief Operating Officer (“COO”). As COO, Gent will be responsible for operational consistency and efficiency across markets and implementation of structural enhancements to facilitate scaling.

This press release features multimedia. View the full release here:

Keep reading... Show less

HempFusion Wellness Inc. (TSX:CBD.U) (“ HempFusion ” or the “ Company ”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its wholly owned subsidiary, Probulin Probiotics, LLC (“ Probulin ”), has increased its product selection in certain brick and mortar locations and expanded its distribution on Amazon through a unique eCommerce store within the Amazon platform. The broader product selection is available in major brick and mortar stores including Sprouts and Fresh Thyme and includes the Company’s new Probulin Total Care Immune product.

This press release features multimedia. View the full release here:

Keep reading... Show less

 MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”) is pleased to report third party confirmatory studies that the active ingredient in MustGrow’s mustard plant-based technology, Allyl Isothiocyanate (“AITC”), has a positive impact on soil health, contributing to the environmental and ecological security of both our plant-based food supply and the planet. Application of natural AITC returns organic plant material to the soil through its pre-plant treatment process as a potential alternative to using synthetic chemicals.

Soil micro-organisms play an important role in soil fertility and plant health, contributing to natural soil processes including the formation of organic matter and nutrient transformation. Human activities, including chemical pesticide use, can adversely impact the soil microbial diversity and structure.

Keep reading... Show less

Heritage Cannabis Holdings Corp. (CSE: CANN) (OTCQX: HERTF) (“Heritage” or the “Company”), today announced that its subsidiary CannaCure Corp. (“CannaCure”) has entered into a binding letter of intent with Entourage Participações S.A. (“Entourage Phytolab”) for a three-year extraction and finished product supply agreement (the “Agreement”) for the distribution of pharmaceutical products in Brazil.

Under the terms of the Agreement, Heritage will supply to Entourage Phytolab, hemp-derived CBD dominant extract, cannabis-derived THC dominant extract, and hemp-derived CBD 25 mg softgels and cannabis-derived THC dominant 2.5 and 5.0 mg softgels.

Keep reading... Show less

Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”) Is pleased to announce its partially owned subsidiary NeonMind (CSE: NEON) (“NeonMind”) has common shares now trading on the Frankfurt Stock Exchange (the “FSE”) under the symbol “6UF”. As a result, NeonMind’s common shares are now cross-listed on the Canadian Securities Exchange and the FSE. Shares of Better Plant are available on the FSE under the symbol “YG3”.

Cannot view this image? Visit:

Keep reading... Show less